| Identification | More | [Name]
Cefeprime dihydrochloride | [CAS]
107648-80-6 | [Synonyms]
CEFEPIME DIHYDROCHLORIDE
CEFEPIME HCL
CEFEPIME HYDROCHLORIDE
CEFEPIME HCL STERILE POWDER
CEFEPRIME DIHYDROCHLORIDE
(6R,7R)-7-[[(2E)-2-(2-Amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid chloride hydrochloride | [EINECS(EC#)]
827-945-9 | [Molecular Formula]
C19H25ClN6O5S2 | [MDL Number]
MFCD06795759 | [Molecular Weight]
517.02 | [MOL File]
107648-80-6.mol |
| Hazard Information | Back Directory | [Description]
Cefepime Hydrochloride is the hydrochloride salt of a semi-synthetic, beta-lactamase-resistant, fourth-generation cephalosporin antibiotic derived from an Acremonium fungal species with broad-spectrum bactericidal activity. Administered parenterally, cefepime inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity, resulting in a reduction of bacterial cell wall stability and cell lysis. This agent is more active against a variety of Gram-positive pathogens compared to third-generation cephalosporins. | [Uses]
Cefepime hydrochloride has been used as a pharmaceutical reference standard for the determination of analytes in pharmaceutical preparations by spectrophotometric and chromatographic techniques. Cefepime is commonly used in the treatment of severe atypical pneumonia and infections caused by multi-drug resistant microorganisms (e.g. Pseudomonas aeruginosa), and is also indicated for the empirical treatment of febrile neutropenia. | [Definition]
ChEBI: Cefepime hydrochloride is a hydrochloride that is the monohydrate of the dihydrochloride salt of cefepime. It has a role as an antibacterial drug. It is a hydrochloride, a hydrate and a cephalosporin. It contains a cefepime(1+). |
|
|